Dpx-Survivac And Intermittent Low-Dose Cyclophosphamide (Cpa) With Or Without Epacadostat (E) In The Treatment Of Subjects With Advanced Recurrent Epithelial Ovarian Cancer (Decide(1) Trial): T Cell Responses And Tumor Infiltration Correlate With Tumor Regression.

Janos Laszlo Tanyi,Oliver Dorigo,Amit M. Oza,James Fredric Strauss,Tanja Pejovic,Sharad A. Ghamande,Prafull Ghatage,Jeannine A. Villella,Stephan Fiset,Lisa Diana MacDonald,Olga Hrytsenko,Marianne Stanford,Robert C Newton,Lance Leopold, Gabriela Nicola Rosu

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 3|浏览40

暂无评分

摘要

5576Background: DPX-Survivac is a novel T cell activating therapy designed to elicit an effective immune response against recurrent ovarian cancers that express the survivin protein. The survivin s...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要